TYSABRI® (natalizumab) Clinical Benefits
Reduced flare-ups
At the end of a 2-year study, TYSABRI reduced how often flare-ups occurred by 67% compared with placebo. The average number of flare-ups a patient had each year was 0.22 for TYSABRI and 0.67 for placebo.
- Of the patients who took TYSABRI in the 2-year study, more than 6 out of 10 had no flare-ups at all (67% of people taking TYSABRI had no flare-ups at the end of the 2-year study, compared with 41% of people taking placebo)
Slowed disability progression
In the same 2-year study, TYSABRI slowed the worsening of physical disability that is common in patients with MS. TYSABRI reduced the chance a person’s physical disability would worsen by 42% compared with placebo.
- 17% of people taking TYSABRI had their physical disability worsen, while 29% of people taking a placebo had their physical disability worsen
- Of people who took TYSABRI in the 2-year study, more than 8 out of 10 had no physical disability progression (83% of people taking TYSABRI had no physical disability progression at the end of the 2-year study, compared with 71% of people taking placebo)
- Reduce the number of new active lesions
- In a 2-year study, 9 out of 10 people taking TYSABRI had no new lesions that show new disease activity* (97% of people taking TYSABRI had no new lesions that showed disease activity, compared with 72% of people taking placebo*)
*Changes in MRI often do not relate to how your MS is progressing.
